KLK3 and prostate carcinoma: The utility of FCH PET/CT to detect recurrent prostate cancer has been demonstrated by several teams since 20059, a special attention being paid to the rate of positive examinations according to PSA levels10–14 or PSA doubling time or velocity15,16, or initial Gleason score.11 In our survey, 51% of the FCH PET/CT was performed for restaging a known recurrence or localising an occult biological recurrence.